Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer

BACKGROUND: There is no single standard chemotherapy regimen for elderly patients with advanced gastric cancer (AGC). A phase III trial has confirmed that both capecitabine monotherapy and capecitabine plus oxaliplatin are well tolerated for elderly patients with AGC, but their economic influence in...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Jingyuan, Tan, Chongqing, Zeng, Xiaohui, Liu, Shikun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023138/
https://www.ncbi.nlm.nih.gov/pubmed/29953476
http://dx.doi.org/10.1371/journal.pone.0199553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023138/
https://www.ncbi.nlm.nih.gov/pubmed/29953476
http://dx.doi.org/10.1371/journal.pone.0199553

Ejemplares similares